• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Medtronic Diabetes Under Investigation

Quote

anonymous

Guest
Heard that regulators are looking at multiple areas of concern. New to the list is practices of getting patients to upgrade pumps when their current device is working fine. We know that has been the practice for years but with the drop in new business upgrade pumps have been a high priority within the business.

We need to change how we do business and have a fresh product cycle of new and competitive products to offer.
 








anonymous said:
Heard that regulators are looking at multiple areas of concern. New to the list is practices of getting patients to upgrade pumps when their current device is working fine. We know that has been the practice for years but with the drop in new business upgrade pumps have been a high priority within the business.

We need to change how we do business and have a fresh product cycle of new and competitive products to offer.
Click to expand...

Excuses why you didn’t hit your number? Go sell.
 




New pump business has been getting decimated for years as new business down over 30% consistently. Complicit corporate insurance fraud with upgrade pumps is a real issue.

Maybe it’s time to sell something else? Wait…new product approvals on hold due to corporate wide quality violations and product recalls.
 




Sales goals have been reduced so much over the last few years solely because patients and doctors no longer want our products. Yet most of the country still not hitting their numbers. As a result the company has cut corners. We’ve got a real problem!

Regulators having a field day at our expense. How many execs have been terminated yet the problems still exist?
 








I thought the new pump and sensor were both coming out in Aug? What’s DA and NC saying about this? Micromanagement is at an all time high. Working for this division was a well paid job until the last 4 years. How are reps surviving with low pay and micromanagement?
 




The reps that are left are the 2nd or 3rd string reps promoted when all the good reps have already left. They think working for Medtronic is still the dream. Division performance reflects that and leadership that still doesn’t get it. Been getting destroyed by start up companies for years now. Time for Medtronic to exit diabetes tech and blow up this failing division.

#leadershipisclueless
 




Top Bottom
Back
Quote